HilleVax, Inc. (HLVX)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
HLVX Chart
HilleVax (HLVX) Upgraded to Strong Buy: What Does It Mean for the Stock?
HilleVax (HLVX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What Makes HilleVax (HLVX) a New Buy Stock
HilleVax (HLVX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
HilleVax, Inc. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by HilleVax (HLVX)
NEW YORK, NY / ACCESSWIRE / August 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.
HilleVax, Inc. (HLVX) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
HilleVax, Inc. Profile
| - Industry | - Sector | Robert M. Hershberg CEO | NASDAQ (NGS) Exchange | 43157M102 CUSIP |
| US Country | 14 Employees | - Last Dividend | - Last Split | 29 Apr 2022 IPO Date |
Overview
HilleVax, Inc. is a clinical-stage biopharmaceutical company that has carved its niche in the development and commercialization of innovative vaccines. The inception of the company roots back to 2019, initially bearing the name MokshaCo, Inc., before rebranding to HilleVax, Inc. in February 2021. Positioned strategically in Boston, Massachusetts, the company dedicates its efforts towards addressing the significant healthcare challenge posed by norovirus and related illnesses, focusing on the prevention of moderate-to-severe acute gastroenteritis. Through its cutting-edge research and dedication, HilleVax, Inc. stands as a beacon of hope in the realm of vaccine development, aiming to usher in a new era of preventive healthcare solutions.
Products and Services
- HIL-214
HilleVax, Inc.'s flagship product, HIL-214, represents a pioneering step forward in the fight against norovirus-related acute gastroenteritis. As a virus-like particle-based vaccine candidate, HIL-214 embodies the company’s commitment to leveraging advanced biotechnological methods for public health. This innovative approach not only aims to mitigate the severity of symptoms associated with moderate-to-severe acute gastroenteritis but also serves as a testament to HilleVax, Inc.'s prowess in the field of biopharmaceuticals. Through HIL-214, HilleVax hopes to greatly reduce the substantial burden that norovirus places on healthcare systems worldwide.
